ALX Oncology Holdings Inc (ALXO): Capital Expenditures
$212.0K
Year ended 2025-12-31
$172.0K
Trailing 12 months to 2026-06-30
-47.0%
3-year compound annual growth
+46.9%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $212.0K | -52.6% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $447.0K | -64.9% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $1.27M | -10.7% | 2026-03-09, From 2023-01-01 |
| 2022-12-31 | $1.43M | +114.3% | 2025-03-06, From 2022-01-01 |
| 2021-12-31 | $666.0K | n/m | 2024-03-07, From 2021-01-01 |
| 2020-12-31 | $31.0K | -91.2% | 2023-03-09, From 2020-01-01 |
| 2019-12-31 | $353.0K | -45.9% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $653.0K | n/a | 2021-03-18, From 2018-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $212.0K | -52.6% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $88.0K | -67.2% |
| Biomea Fusion, Inc. (BMEA) | 2024-12-31 | $362.0K | -89.3% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $0 | -100.0% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $542.0K | -46.4% |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | $40.0K | +60.0% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $72.0K | +75.6% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $0 | -100.0% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $3.57M | +160.5% |
Compare ALXO, RANI, BMEA, PRPH side by side · Screen every company in Pharmaceutical Preparations ↗